Lantheus Holdings has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of PyL, an investigational imaging agent used to locate prostate cancer lesions. The new drug application (NDA) sent to the FDA includes a request for priority review, which if granted may shorten PyL’s regulatory review process from the usual 10 months to six. Lantheus expects the FDA’s decision on this filing in early December. “The completion of our NDA…
You must be logged in to read/download the full post.
The post Lantheus Seeks FDA Approval of PyL Prostate Cancer Imaging Agent appeared first on BioNewsFeeds.